Up till now, all Alzheimer’s drugs have only helped with the symptoms of the insidious disease, but a new drug called aducanumab, also known as Aduhelm, is intended to slow the progression of Alzheimer’s.
The FDA has given its approval under their “accelerated approval” program, which allows for the ‘faster approval of a drug for a serious or life-threatening illness, even though more study into the drug’s benefits may be needed.’
‘It is a new day,” Harry Johns, CEO of the Alzheimer’s Association, said in a statement. “This approval allows people living with Alzheimer’s more time to live better. For families it means being able to hold on to their loved ones longer. It is about reinvigorating scientists and companies in the fight against this scourge of a disease. It is about hope.”
Biogen, the drug manufacturer estimates about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug.
But for approximately six million people in the U.S. and 30 million globally who have Alzheimer’s, this drug offers hope.